Rosuvastatin-Based Combination Treatment with Acetylsalicylic Acid or Ezetimibe in the Management of Patients at High and Very High Cardiovascular Risk. Expert Opinion Paper of the Polish Lipid Association 2025

• Published in: Archives of medical science 2025-01
• Main Authors: Banach, Maciej, Surma, Stanisław, Bielecka-Dąbrowa, Agata, Gierlotka, Marek, Główczyńska, Renata, Jankowski, Piotr, Jóźwiak, Jacek, Kubica, Jacek, Streb, Witold, Szymański, Filip M, Tomasik, Tomasz, Gil, Robert
• Format: Article
• Language: English
• ISSN: 1734-1922; 1896-9151
• DOI: 10.5114/aoms/199826

Lipid disorders are the most common risk factor for ASCVD in Poland, where it is responsible for up to 200,000 deaths/year, with the number of MI and strokes reaching 80,000 annually and 25% of people dying within 3 years after MI. The level of control of LDL-C is low, at only about 20% among high- and very high-risk patients who often require combination LLT with a potent statin and ezetimibe. Moreover, in Poland, even as many as several million patients require concomitant LLT and antiplatelet (acetylsalicylic acid) therapy in view of their risks and indications. SPC improve adherence to treatment and the achievement of therapeutic goals and allow a greater reduction in cardiovascular incidents and mortality. This PoLA Expert Opinion Paper, is a practical recommendation on how to more effectively treat patients with indications for LLT and antiplatelet therapy using available rosuvastatin-based combination therapies (with ezetimibe or acetylsalicylic acid).